v3.26.1

Fees Summary	Jul. 29, 2026 USD ($)
Fees Summary [Line Items]
Total Offering	$ 331,200,000.00
Previously Paid Amount	13,810.00
Total Fee Amount	45,738.72
Total Offset Amount	0.00
Net Fee	$ 31,928.72
Offering Table N/A
Offset Table N/A	N/A
Combined Prospectus Table N/A	N/A

No definition available.

Name:	ffd_CombinedProspectusTableNa
Namespace Prefix:	ffd_
Data Type:	ffd:naItemType
Balance Type:	na
Period Type:	duration

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

No definition available.

No definition available.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Name:	ffd_TtlFeeAmt
Namespace Prefix:	ffd_
Data Type:	ffd:nonNegative1TMonetary2ItemType
Balance Type:	na
Period Type:	duration

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Name:	ffd_TtlOfferingAmt
Namespace Prefix:	ffd_
Data Type:	ffd:nonNegative1TMonetary2ItemType
Balance Type:	na
Period Type:	duration

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Name:	ffd_TtlOffsetAmt
Namespace Prefix:	ffd_
Data Type:	ffd:nonNegative1TMonetary2ItemType
Balance Type:	na
Period Type:	duration

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230

Name:	ffd_TtlPrevslyPdAmt
Namespace Prefix:	ffd_
Data Type:	ffd:nonNegative1TMonetary2ItemType
Balance Type:	na
Period Type:	duration

Latigo Biotherapeutics, Inc. S-1/A